Automated Immunoassay System receives CE marking

Laboratory products

Automated Immunoassay System receives CE marking

05 Aug, 2013

Published over 12 years ago. See the latest and most current information on Laboratory products.

bioMérieux, a world leader in the field of in vitro diagnostics, has been granted CE marking for its new VIDAS® 3 automated immunoassay system. The latest addition to the VIDAS range offers increased automation capabilities and greater traceability, particularly for pre-analytical sample handling.

VIDAS 3 has been designed to help healthcare professionals meet the new challenges of a rapidly changing regulatory and economic environment. The user-friendly system enables laboratories to carry out on-demand testing 24 hours a day, improving assay performance and turnaround times for both routine and urgent tests. It provides accurate and reliable results, using the same reagents as the other instruments in the VIDAS range, with over 98 tests currently available.

The system features an intuitive, customisable touch screen interface and includes a built-in quality control program to simplify day-­to­-day performance monitoring. In association with bioMerieux’s myQC quality control product, this will enable laboratories to compare their results with those of hundreds of other laboratories, helping to ensure a rapid and reliable response to clinicians’ requests.

To learn more about VIDAS 3, or to join the VIDAS system users community, click here.

ILM Guide 2026/27

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
Do we need to widen our sampling sources for PFAS contamination?
Explore more Arrow
Pollution Solutions Online
Next-generation reverse osmosis membranes for more efficient and cost-effective seawater desalination
Explore more Arrow
Petro Online
Three generations of innovation. One powerful new platform
Explore more Arrow
Chromatography Today
Wiley expands forensic drug database for faster identification of designer drugs
Explore more Arrow